利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.031 秒)

    Methods and systems for accessing the pericardial space
    4.
    发明授权
    Methods and systems for accessing the pericardial space 有权
    用于获取心包空间的方法和系统

    公开(公告)号：US08000807B2

    公开(公告)日：2011-08-16

    申请号：US12815624

    申请日：2010-06-15

    申请人： Mary M Morris ,  Kenneth C. Gardeski ,  Michael R. Ujhelyi ,  Michael E. Leckrone

    发明人： Mary M Morris ,  Kenneth C. Gardeski ,  Michael R. Ujhelyi ,  Michael E. Leckrone

    IPC分类号： A61N1/05 ,  A61B18/00

    CPC分类号： A61B17/3478 ,  A61B17/00234 ,  A61B17/3417 ,  A61B18/1492 ,  A61B2017/00247 ,  A61B2017/003 ,  A61B2017/22077 ,  A61B2017/3484 ,  A61B2017/3488 ,  A61B2017/349 ,  A61B2018/00291 ,  A61B2018/00357 ,  A61B2018/00392 ,  A61M25/0084 ,  A61M2025/0037

    摘要： Methods and systems for transvenously accessing the pericardial space via the vascular system and atrial wall, particularly through the superior vena cava and right atrial wall, to deliver treatment in the pericardial space are disclosed. A steerable instrument is advanced transvenously into the right atrium of the heart, and a distal segment is deflected into the right atrial appendage. A fixation catheter is advanced employing the steerable instrument to affix a distal fixation mechanism to the atrial wall. A distal segment of an elongated medical device, e.g., a therapeutic catheter or an electrical medical lead, is advanced through the fixation catheter lumen, through the atrial wall, and into the pericardial space. The steerable guide catheter is removed, and the elongated medical device is coupled to an implantable medical device subcutaneously implanted in the thoracic region. The fixation catheter may be left in place.

    摘要翻译： 公开了通过血管系统和心房壁，特别是通过上腔静脉和右心房壁经心脏进入心包空间的方法和系统，以在心包空间中递送治疗。 一个可操纵的器械被递送到心脏的右心房，远端部分被偏转到右心耳。 使用可操纵的器械来前进固定导管，以将远端固定机构固定在心房壁上。 细长医疗装置（例如治疗性导管或电气医用引线）的远端部分通过固定导管内腔前进通过心房壁并进入心包空间。 可移动的导向导管被移除，并且细长的医疗装置被联接到皮下植入胸部区域的可植入医疗装置。 固定导管可以留在原位。

    Apparatus and system for delivery of drug therapies
    6.
    发明授权
    Apparatus and system for delivery of drug therapies 有权
    用于药物治疗的装置和系统

    公开(公告)号：US07722598B2

    公开(公告)日：2010-05-25

    申请号：US11675693

    申请日：2007-02-16

    申请人： Michael R. Ujhelyi ,  Rahul Mehra ,  Xiaoyi Min

    发明人： Michael R. Ujhelyi ,  Rahul Mehra ,  Xiaoyi Min

    IPC分类号： A61K9/22

    CPC分类号： A61M5/14276 ,  A61M5/14244 ,  A61M5/16813 ,  A61M2205/0266 ,  A61N1/0568

    摘要： A medical delivery system for delivering a fluid to a desired location within a body that includes a first member having an aperture, and a second member adapted to be positioned over the first member. The fluid to be delivered is contained within a fluid storage device, formed by at least one of the first member and the second member. The medical delivery system includes means for repositioning the first member relative to the second member between a first state preventing passage of the fluid through the aperture and a second state enabling passage of the fluid outward from the fluid storage device through the aperture.

    摘要翻译： 一种用于将流体输送到包括具有孔的第一构件的主体内的期望位置的医疗输送系统，以及适于定位在第一构件上方的第二构件。 待输送的流体被包含在由第一构件和第二构件中的至少一个形成的流体存储装置内。 医疗输送系统包括用于在通过孔的流体的第一状态阻止通道和允许流体从流体存储装置向外通过孔的第二状态之间相对于第二构件重新定位第一构件的装置。

    DELIVERY OF A SYMPATHOLYTIC CARDIOVASCULAR AGENT TO THE CENTRAL NERVOUS SYSTEM
    7.
    发明申请
    DELIVERY OF A SYMPATHOLYTIC CARDIOVASCULAR AGENT TO THE CENTRAL NERVOUS SYSTEM 有权
    向中央神经系统递送病理性心脏血管代谢

    公开(公告)号：US20080228133A1

    公开(公告)日：2008-09-18

    申请号：US12128046

    申请日：2008-05-28

    申请人： KEITH R. HILDEBRAND ,  Michael R. Ujhelyi ,  Xiaohong Zhou ,  Daniel C. Sigg ,  Linda M. Page

    发明人： KEITH R. HILDEBRAND ,  Michael R. Ujhelyi ,  Xiaohong Zhou ,  Daniel C. Sigg ,  Linda M. Page

    IPC分类号： A61M31/00

    CPC分类号： A61M5/142 ,  A61M5/14276 ,  A61M5/1723 ,  A61M2005/14208 ,  A61M2205/3523 ,  A61M2230/00 ,  A61M2230/04 ,  A61M2230/63 ,  A61N1/3962

    摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).

    摘要翻译： 由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解急性或慢性心脏损伤或心脏功能受损的症状。 药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。 患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与心脏损伤相关的生理参数或心脏功能受损并触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。 交感神经心血管药剂是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂（例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫索尼定，甲基多巴，甲苯噻嗪，胍法西林，美托洛尼，美托咪定和 右美托咪定）。

    Delivery of a sympatholytic cardiovascular agent to the central nervous system
    10.
    发明授权
    Delivery of a sympatholytic cardiovascular agent to the central nervous system 有权
    交配性心血管药物向中枢神经系统递送

    公开(公告)号：US08348884B2

    公开(公告)日：2013-01-08

    申请号：US12128046

    申请日：2008-05-28

    申请人： Keith R. Hildebrand ,  Michael R. Ujhelyi ,  Xiaohong Zhou ,  Daniel C. Sigg ,  Linda M. Page

    发明人： Keith R. Hildebrand ,  Michael R. Ujhelyi ,  Xiaohong Zhou ,  Daniel C. Sigg ,  Linda M. Page

    IPC分类号： A61M31/00

    CPC分类号： A61M5/142 ,  A61M5/14276 ,  A61M5/1723 ,  A61M2005/14208 ,  A61M2205/3523 ,  A61M2230/00 ,  A61M2230/04 ,  A61M2230/63 ,  A61N1/3962

    摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).

    摘要翻译： 由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解急性或慢性心脏损伤或心脏功能受损的症状。 药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。 患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与心脏损伤相关的生理参数或心脏功能受损并触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。 交感神经心血管药物是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂（例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫索尼定，甲基多巴，甲苯噻嗪，胍法西汀，脱甲基丸，美托咪定和 右美托咪定）。